2027 Compounding Pharmaceutical Companies 
STAT
DECEMBER 7, 2023
But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
pharmaphorum
JANUARY 27, 2023
An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 16, 2023
Ageing will only compound the challenge: high income country populations are already old, but between 2015 and 2050, the proportion of the world’s population aged over 60 will nearly double, from 12% to 22%, and, by 2050, 80% of older people will be living in low- and middle-income countries. Innovation will power the market.
Pharmaceutical Technology
JANUARY 10, 2023
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.
Pharmaceutical Technology
APRIL 24, 2023
Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. As a result, some pharmaceutical companies are turning to third parties. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027.
Expert insights. Personalized for you.
305 
Let's personalize your content